MAPESolutions is constantly improving to be recognized, throughout Latin America, as the main company in the segment to present innovative solutions aimed at the sustainability of health systems.
Opening Hours
Mon – Fri: 08.00 – 17.00
E-mail: contato@mapesolutions.com
Copyright © Mapes - Powered by Traction
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
[:pb]The incorporation of technologies in the healthcare sector is a complex process and requires careful study.Healthcare Technology Assessments (HTA), already fulfil this role in many countries and, in Brazil, they are mandatory for medicines, procedures or equipment’s to be adopted by the Unified Health System (SUS). However, even with all the necessary steps in an HTA, which include technical analysisand health economics, among others, the adoption of a new technology brings a series of uncertainties.
Especially in times of financial crisis, a new drug, procedure or equipment is seen as a risk to the medical community. A tool that can reduce these risks for the parties involved and, thus, encourage the adoption of new technologies in the sector, is the so-called risk sharing (sharing contract or sharing of risks). Understand more in this article.
What’srisk sharing
As this is a new model, there is no fully established concept for risk sharing, butHealthcare Technology Assessment International (HTAi) defines it, briefly, as an agreement between the producer and the payer for access to a technology in accordance with certain conditions. These contracts can use a variety of mechanisms to address uncertainty about the technology’s performance, to maximize its use, or even minimize its financial impact.
No matter what form the deal takes, the risk will always be on the manufacturer’s or the payer’s side, and never on the patients’ side. The idea, on the contrary, is that the final public benefits from the possibility of choice and access to adequate treatment, without any prejudice.
In this way, risk sharing contracts can be basically divided into:
Use of risk sharing in cancer drugs
One of the reasons for using risk sharing contracts is to allow patients’ access to certain technologies without compromising the sustainability of the healthcare system, as occurs with drugs for the treatment of cancer. A study carried out in Italy showed that the use of this type of contract resulted in a reduction of 259 days (from 343 to 84) in the average authorization time for cancer drugs. According to another Italian survey, one in two doctors believe in risk-sharing agreements (APR) as the right path.
The use of risk sharing can also be indicated for technologies with different indications and applied to different populations. This happens, for example, with cancer drugs: in 2014, more than 50% of them were approved for more than one type of cancer. By 2020, this percentage is expected to rise to 75%.
If the same drug can have different results according to the indication and line of treatment, one would imagine that its value would also vary. However, this is not what usually happens and, thus, it opens up the possibility that some drugs will never be developed for a particular indication, as they are not financially interesting. Risk-sharing contracts can also be an important tool in this task, being applied by indication and, thus, contributing to the so-called definition of price by indication (PPI).
Drug combinations
Another situation in which risk sharing contracts can help with pricing is the combination of different drugs into a single product. This is important for diseases such as cancer, HIV, hepatitis C and diabetes, on which there are constant studies and, consequently, each day more combinations to be tested. This importance is even greater when it comes to bringing together drugs from different manufacturers, as the risks can be shared between more than one company.
The Portuguese experience
In Portugal, risk-sharing contracts have already been used, for example, for medicines for diseases such as melanoma, rheumatoid arthritis, hepatitis C and breast cancer. In the case of hepatitis C, risk sharing brought clinical benefits to patients and, consequently, reduced treatment costs, as the disease started to bring fewer complications.
Example de risk sharing in Brazil
An example of the application of this model in Brazil was a partnership between UNIMED São José do Rio Preto and GSK Oncologia, which enabled breast cancer patients to have access to a new drug. In case of successful treatment, the health plan pays for the drug. Otherwise, the cost is a responsibility of the manufacturer, which gives even more reasons for the industry to develop an effective product
In the context of public health, the model was adopted for the new treatment offered to SUS patients diagnosed with hepatitis C.
To learn more about our solutions for incorporating healthcare technologies, download the MAPES e-book: MAPES: Cases &Soluções.[:]
Recent Posts
Popular Post
Como a tecnologia pode garantir o conceito
20/10/2021Importance of monitoring the clinical outcome of
15/03/2021The importance of economic evaluation in the
19/01/2021Popular Categories
Archives